BerandaALNY • NASDAQ
add
Alnylam Pharmaceuticals, Inc.
Tutup sebelumnya
$240,55
Rentang hari
$232,82 - $240,17
Rentang tahun
$141,98 - $304,39
Kapitalisasi pasar
30,69Â M USD
Volume Rata-Rata
599,20Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 500,92Â jt | -33,26% |
Biaya operasional | 491,92Â jt | 8,75% |
Laba bersih | -111,57Â jt | -175,51% |
Margin laba bersih | -22,27 | -213,10% |
Penghasilan per saham | -0,50 | -128,74% |
EBITDA | -62,92Â jt | -127,70% |
Tarif pajak efektif | -2,68% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 2,78Â M | 15,54% |
Total aset | 4,21Â M | 9,53% |
Total liabilitas | 4,17Â M | 4,19% |
Total ekuitas | 32,35 jt | — |
Saham yang beredar | 128,98 jt | — |
Harga terhadap nilai buku | 962,20 | — |
Tingkat pengembalian aset | -4,68% | — |
Tingkat pengembalian modal | -7,04% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -111,57Â jt | -175,51% |
Kas dari operasi | 43,71Â jt | -87,84% |
Kas dari investasi | -30,25Â jt | -181,03% |
Kas dari pembiayaan | 102,76Â jt | 210,08% |
Perubahan kas bersih | 131,30Â jt | -65,01% |
Arus kas bebas | 108,49Â jt | -51,41% |
Tentang
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Didirikan
14 Jun 2002
Situs
Karyawan
2.100
